oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2019-18-5-86-96oncotomsk-1194Research ArticleОБЗОРЫREVIEWSЗАБРЮШИННЫЕ НЕОРГАННЫЕ ЛИПОСАРКОМЫ: СОВРЕМЕННЫЙ ВЗГЛЯД НА ПРОБЛЕМУRETROPERITONEAL NON-ORGAN LIPOSARCOMAS: THE MODERN CONCEPTВолковА. Ю.VolkovA. Yu.

Волков Александр Юрьевич, аспирант хирургического отделения № 6 (абдоминальной онкологии) торако-абдоминального отдела, НИИ клинической онкологии им. Н.Н. Трапезникова

115478, г. Москва, Каширское шоссе, 23

 

Alexander Yu. Volkov, MD, Postgraduate, Surgical Department № 6 (abdominal oncology) of Thoracoabdominal Department

23, Kashirskoye shosse, 115478, Moscow

79164577128@yandex.ruНередС. Н.NeredS. N.

Неред Сергей Николаевич, доктор медицинских наук, ведущий научный сотрудник хирургического отделения № 6 (абдоминальной онкологии) торако-абдоминального отдела, НИИ клинической онкологии им. Н.Н. Трапезникова

115478, г. Москва, Каширское шоссе, 23

SPIN-код: 4588-3230

AuthorID (РИНЦ): 394472

 

Sergei N. Nered, MD, DSc, Leading researcher of the Surgical Department № 6 (abdominal oncology) of Thoracoabdominal Department

23, Kashirskoye shosse, 115478, Moscow

nered@mail.ruЛюбченкоЛ. Н.LyubchenkoL. N.

Любченко Людмила Николаевна, доктор медицинских наук, доцент кафедры онкологии института клинической медицины, ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России; заведующая лабораторией клинической онкогенетики отдела морфологической и молекулярно-генетической диагностики опухолей, НИИ клинической онкологии им. Н.Н. Трапезникова, ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России

115478, г. Москва, Каширское шоссе, 23,

119991, Москва, ул. Трубецкая, 8/2

SPIN-код: 9589-9057

AuthorID (РИНЦ): 140311

Lyudmila N. Lyubchenko, MD, DSc, Associate Professor of the Oncology, Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation; Head of the Laboratory of Clinical Oncogenetics of the Department of Morphological and Molecular Genetic Diagnosis of Tumors, N.N. Blokhin National Medical Research Centre of oncology of the Health Ministry of Russia

23, Kashirskoye shosse, 115478, Moscow,

8-2, Trubetskaya Street, 119991, Moscow

clingen@mail.ruФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN. N. Blokhin National Medical Research Centre of Oncology, Health Ministry of RussiaRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России; ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава РоссииРоссияN. N. Blokhin National Medical Research Centre of Oncology, Health Ministry of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian FederationRussian Federation2019011120191858696Copyright © Волков А.Ю., Неред С.Н., Любченко Л.Н., 20192019Волков А.Ю., Неред С.Н., Любченко Л.Н.Volkov A.Y., Nered S.N., Lyubchenko L.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1194

Цель исследования – провести систематический обзор данных мировой литературы, включающий все аспекты, которые характеризуют забрюшинные неорганные липосаркомы и необходимы для понимания проблемы.

Материал и методы

Материал и методы. Поиск информационных источников произведен в системах Pubmed, Elibrary, COSMIC cancer database. Проанализированы данные ретроспективных и проспективных клинических исследований. В работе отражен опыт российских и зарубежных исследователей.

Результаты

Результаты. В обзоре представлены современные данные об эпидемиологии, классификациях, клинико-морфологических и молекулярно-генетических характеристиках, особенностях диагностики и лечения забрюшинных неорганных липосарком.

Заключение

Заключение. Забрюшинные саркомы составляют около 13 % от всех видов сарком мягких тканей. Липосаркома – наиболее часто встречающаяся забрюшинная мезенхимальная опухоль. Проблема диагностики и лечения неорганных забрюшинных липосарком является актуальной, поскольку отдаленные результаты лечения этой патологии неудовлетворительны. По мере накопления опыта, связанного с диагностикой и лечением забрюшинных неорганных липосарком, происходят изменения в системе понимания проблемы, определяющей стратегию оказания медицинской помощи данной категории пациентов. В статье представлены современные концепции забрюшинных неорганных липосарком.

Objective

Objective: to conduct a systematic literature review of the published studies on retroperitoneal non-organ liposarcomas.

Material and Methods

Material and Methods. A literature search was performed using Pubmed, Elibrary, COSMIC databases. The data of retrospective and prospective clinical trials were analyzed. Results. The article reviews contemporary data on epidemiology, classification, clinicalmorphological and molecular-genetic characteristics, as well as diagnosis and treatment of retroperitoneal non-organ liposarcomas. Conclusion. Retroperitoneal sarcomas account for about 13 % of all types of soft tissue sarcomas. Liposarcoma is the most common retroperitoneal mesenchymal tumor. Diagnosis and treatment of non-organ retroperitoneal liposarcoma remain challenging due to poor long-term treatment outcomes. As experience is gained with the diagnosis and treatment of retroperitoneal nonorganic liposarcomas, changes occur in the system of understanding the problem that determines the strategy for providing medical care in this category of patients. The article presents modern concept of retroperitoneal non-organ liposarcomas.

липосаркоманеорганные забрюшинные опухоликлассификациямолекулярно-генетические характеристикидиагностикалечениеэпидемиологиялучевая терапияпрогнозвыживаемостьliposarcomaextra-organ retroperitoneal tumorsclassificationmolecular genetic characteristicsdiagnosistreatmentepidemiologyradiation therapyprognosissurvivalReferencesMirilas P., Skandalakis J.E. Surgical anatomy of the retroperitoneal spaces-part I: embryogenesis and anatomy. Am Surg. 2009 Nov; 75(11): 1091–7.Mirilas P., Skandalakis J.E. Surgical anatomy of the retroperitoneal spaces-part I: embryogenesis and anatomy. Am Surg. 2009 Nov; 75(11): 1091–7.Федоров В.Д., Цвиркун В.В. Хирургическое лечение больных с неорганными забрюшинными опухолями. Актуальные вопросы хирургии. Сборник научных трудов к 50-летию Института хирургии им. А.В. Вишневского РАМН. М., 214.Fedorov V.D., Tsvirkun V.V. Surgical treatment of patients with inorganic retroperitoneal tumors. Actual issues of surgery. Collection of scientific papers on the 50th anniversary of the Institute of Surgery. A.V. Vishnevsky RAMS. Moscow, 214. (in Russian).Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. М., 2018. 236.Kaprin A.D., Starinskii V.V., Petrova G.V. The status of cancer care for the population of Russia in 2017. Moscow, 2018. 236. (in Russian).Barretina J., Taylor B.S., Banerji S., Ramos A.H., Lagos-Quintana M., Decarolis P.L., Shah K., Socci N.D., Weir B.A., Ho A., Chiang D.Y., Reva B., Mermel C.H., Getz G., Antipin Y., Beroukhim R., Major J.E., Hatton C., Nicoletti R., Hanna M., Sharpe T., Fennell T.J., Cibulskis K., Onofrio R.C., Saito T., Shukla N., Lau C., Nelander S., Silver S.J., Sougnez C., Viale A., Winckler W., Maki R.G., Garraway L.A., Lash A., Greulich H., Root D.E., Sellers W.R., Schwartz G.K., Antonescu C.R., Lander E.S., Varmus H.E., Ladanyi M., Sander C., Meyerson M., Singer S. Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy. Nat Genet. 2010 August; 42(8): 715–721. doi: 10.1038/ng.619.Barretina J., Taylor B.S., Banerji S., Ramos A.H., Lagos-Quintana M., Decarolis P.L., Shah K., Socci N.D., Weir B.A., Ho A., Chiang D.Y., Reva B., Mermel C.H., Getz G., Antipin Y., Beroukhim R., Major J.E., Hatton C., Nicoletti R., Hanna M., Sharpe T., Fennell T.J., Cibulskis K., Onofrio R.C., Saito T., Shukla N., Lau C., Nelander S., Silver S.J., Sougnez C., Viale A., Winckler W., Maki R.G., Garraway L.A., Lash A., Greulich H., Root D.E., Sellers W.R., Schwartz G.K., Antonescu C.R., Lander E.S., Varmus H.E., Ladanyi M., Sander C., Meyerson M., Singer S. Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy. Nat Genet. 2010 August; 42(8): 715–721. doi: 10.1038/ng.619.Liles J.S., Tzeng C.W., Short J.J., Kulesza P., Heslin M.J. Retroperitoneal and intra-abdominal sarcoma. Curr Probl Surg. 2009 Jun; 46(6): 445–503. doi: 10.1067/j.cpsurg.2009.01.004.Liles J.S., Tzeng C.W., Short J.J., Kulesza P., Heslin M.J. Retroperitoneal and intra-abdominal sarcoma. Curr Probl Surg. 2009 Jun; 46(6): 445–503. doi: 10.1067/j.cpsurg.2009.01.004.Dalal K.M., Kattan M.W., Antonescu C.R., Brennan M.F., Singer S. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, ortrunk. Ann Surg. 2006 Sep; 244(3): 381–91. doi: 10.1097/01.sla.0000234795.98607.00.Dalal K.M., Kattan M.W., Antonescu C.R., Brennan M.F., Singer S. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, ortrunk. Ann Surg. 2006 Sep; 244(3): 381–91. doi: 10.1097/01.sla.0000234795.98607.00.Gadgeel S.M., Harlan L.C., Zeruto C.A., Osswald M., Schwartz A.G. Patterns of care in a population-based sample of soft tissue sarcoma patients in the United States. Cancer. 2009 Jun 15; 115(12): 2744–54. doi: 10.1002/cncr.24307.Gadgeel S.M., Harlan L.C., Zeruto C.A., Osswald M., Schwartz A.G. Patterns of care in a population-based sample of soft tissue sarcoma patients in the United States. Cancer. 2009 Jun 15; 115(12): 2744–54. doi: 10.1002/cncr.24307.Kindblom L.G., Angervall L., Svendsen P. Liposarcoma: a clinicopathologic, radio-graphic and prognostic study. Acta Pathol Microbiol Scand (Suppl.) 1975; 253: 1–71.Kindblom L.G., Angervall L., Svendsen P. Liposarcoma: a clinicopathologic, radio-graphic and prognostic study. Acta Pathol Microbiol Scand (Suppl.) 1975; 253: 1–71.Dei Tos A.P. Liposarcomas: diagnostic pitfalls and new insights. Histopathology. 2014 Jan; 64(1): 3852. doi: 10.1111/his.12311.Dei Tos A.P. Liposarcomas: diagnostic pitfalls and new insights. Histopathology. 2014 Jan; 64(1): 3852. doi: 10.1111/his.12311.Fletcher C.D., Bridge J.A., Hogendoorn P., Mertens F. World Health Organization Classification of Tumours; Pathology and Genetics. Tumours of Soft Tissue and Bone. Geneva, 2013. 468 p.Fletcher C.D., Bridge J.A., Hogendoorn P., Mertens F. World Health Organization Classification of Tumours; Pathology and Genetics. Tumours of Soft Tissue and Bone. Geneva, 2013. 468 p.Неред С.Н., Стилиди И.С., Клименков А.А., Болотский В.И., Анурова О.А. Клинико-морфологические особенности и результаты хирургического лечения забрюшинных неорганных липосарком. Вопросы онкологии. 2012; 58(1): 94–100.Nered S.N., Stilidi I.S., Klimenkov A.A., Bolotsky V.I., Anurova O.A. Clinico-morphological properties and surgical treatment results in retroperitoneal liposarcomas. Problems in Oncology. 2012; 58(1): 94–100. (in Russian).Lewis J.J., Leung D., Woodruff J.M., Brennan M.F. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998 Sep; 228(3): 355–65. doi: 10.1097/00000658199809000-00008.Lewis J.J., Leung D., Woodruff J.M., Brennan M.F. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998 Sep; 228(3): 355–65. doi: 10.1097/00000658199809000-00008.Stoeckle E., Coindre J.M., Bonvalot S., Kantor G., Terrier P., Bonichon F., Nguyen Bui B.; French Federation of Cancer Centers Sarcoma Group. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer. 2001 Jul; 92(2): 359–68. doi: 10.1002/1097-0142(20010715)92:2<359::aid-cncr1331>3.0.co;2-y.Stoeckle E., Coindre J.M., Bonvalot S., Kantor G., Terrier P., Bonichon F., Nguyen Bui B.; French Federation of Cancer Centers Sarcoma Group. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer. 2001 Jul; 92(2): 359–68. doi: 10.1002/1097-0142(20010715)92:2<359::aid-cncr1331>3.0.co;2-y.Афанасьев С.Г., Добродеев А.Ю., Волков М.Ю. Результаты хирургического лечения неорганных забрюшинных опухолей. Сибирский онкологический журнал. 2015; 3: 51–54.Afanasyev S.G., Dobrodeev A.Yu., Volkov M.Yu. Surgical treatment outcomes of nonorganic retroperitoneal tumors. Siberian Journal of Oncology. 2015; 3: 51–54. (in Russian).Matthew R. Lindberg. Diagnostic Pathology: Soft Tissue Tumors 2nd edition. Сanada, 2015. 800 p.Matthew R. Lindberg. Diagnostic Pathology: Soft Tissue Tumors 2nd edition. Сanada, 2015. 800 p.Kilpatrick S.E., Doyon J., Choong P.F., Sim F.H., Nascimento A.G. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer 1996 Apr; 77 (8): 1450–8. doi: 10.1002/(SICI)1097-0142(19960415)77:8<1450::AID-CNCR5>3.0.CO;2-G.Kilpatrick S.E., Doyon J., Choong P.F., Sim F.H., Nascimento A.G. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer 1996 Apr; 77 (8): 1450–8. doi: 10.1002/(SICI)1097-0142(19960415)77:8<1450::AID-CNCR5>3.0.CO;2-G.Weiss S.W., Rao V.K. Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites. A follow-up study of 92 cases with analysis of the incidence of “dedifferentiation”. Am J Surg Pathol 1992 Nov; 16(11): 1051–8. doi: 10.1097/00000478-199211000-00003.Weiss S.W., Rao V.K. Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites. A follow-up study of 92 cases with analysis of the incidence of “dedifferentiation”. Am J Surg Pathol 1992 Nov; 16(11): 1051–8. doi: 10.1097/00000478-199211000-00003.Canter R.J., Qin L.X., Ferrone C.R., Maki R.G., Singer S., Brennan M.F. Why do patients with low-grade soft tissue sarcoma die? Ann Surg Oncol. 2008 Dec; 15(12): 3550–60. doi: 10.1245/s10434-008-0163-0.Canter R.J., Qin L.X., Ferrone C.R., Maki R.G., Singer S., Brennan M.F. Why do patients with low-grade soft tissue sarcoma die? Ann Surg Oncol. 2008 Dec; 15(12): 3550–60. doi: 10.1245/s10434-008-0163-0.Thway K., Flora R., Shah C., Olmos D., Fisher C. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012 Mar; 36(3): 462–9. doi: 10.1097/PAS.0b013e3182417330.Thway K., Flora R., Shah C., Olmos D., Fisher C. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012 Mar; 36(3): 462–9. doi: 10.1097/PAS.0b013e3182417330.Dei Tos A.P., Doglioni C., Piccinin S., Sciot R., Furlanetto A., Boiocchi M., Dal Cin P., Maestro R., Fletcher C.D., Tallini G. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol. 2000 Apr; 190(5): 531–6. doi: 10.1002/(SICI)1096-9896(200004)190:5<531::AIDATH579>3.0.CO;2-W.Dei Tos A.P., Doglioni C., Piccinin S., Sciot R., Furlanetto A., Boiocchi M., Dal Cin P., Maestro R., Fletcher C.D., Tallini G. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol. 2000 Apr; 190(5): 531–6. doi: 10.1002/(SICI)1096-9896(200004)190:5<531::AIDATH579>3.0.CO;2-W.Italiano A., Bianchini L., Keslair F., Bonnafous S., Cardot-Leccia N., Coindre J.M., Dumollard J.M., Hofman P., Leroux A., Mainguené C., Peyrottes I., Ranchere-Vince D., Terrier P., Tran A., Gual P., Pedeutour F. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer. 2008 May; 122(10): 2233–41. doi: 10.1002/ijc.23380.Italiano A., Bianchini L., Keslair F., Bonnafous S., Cardot-Leccia N., Coindre J.M., Dumollard J.M., Hofman P., Leroux A., Mainguené C., Peyrottes I., Ranchere-Vince D., Terrier P., Tran A., Gual P., Pedeutour F. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer. 2008 May; 122(10): 2233–41. doi: 10.1002/ijc.23380.Sirvent N., Coindre J.M., Maire G., Hostein I., Keslair F., Guillou L., Ranchere-Vince D., Terrier P., Pedeutour F. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007 Oct; 31(10): 1476–89. doi: 10.1097/PAS.0b013e3180581fff.Sirvent N., Coindre J.M., Maire G., Hostein I., Keslair F., Guillou L., Ranchere-Vince D., Terrier P., Pedeutour F. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007 Oct; 31(10): 1476–89. doi: 10.1097/PAS.0b013e3180581fff.Tap W.D., Eilber F.C., Ginther C., Dry S.M., Reese N., BarzanSmith K., Chen H.W., Wu H., Eilber F.R., Slamon D.J., Anderson L. Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer. 2011 Feb; 50(2): 95–112. doi: 10.1002/gcc.20835.Tap W.D., Eilber F.C., Ginther C., Dry S.M., Reese N., BarzanSmith K., Chen H.W., Wu H., Eilber F.R., Slamon D.J., Anderson L. Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer. 2011 Feb; 50(2): 95–112. doi: 10.1002/gcc.20835.Louis-Brennetot C., Coindre J.M., Ferreira C., Perot G., Terrier P., Aurias A. The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors. Genes Chromosomes Cancer. 2011 Nov; 50(11): 896–907. doi: 10.1002/gcc.20909.Louis-Brennetot C., Coindre J.M., Ferreira C., Perot G., Terrier P., Aurias A. The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors. Genes Chromosomes Cancer. 2011 Nov; 50(11): 896–907. doi: 10.1002/gcc.20909.Lee S.E., Kim Y.J., Kwon M.J., Choi D.I., Lee J., Cho J., Seo S.W., Kim S.J., Shin Y.K., Choi Y.L. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. Histol Histopathol. 2014 Jan; 29(1): 127–38. doi: 10.14670/HH-29.127.Lee S.E., Kim Y.J., Kwon M.J., Choi D.I., Lee J., Cho J., Seo S.W., Kim S.J., Shin Y.K., Choi Y.L. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. Histol Histopathol. 2014 Jan; 29(1): 127–38. doi: 10.14670/HH-29.127.Singer S., Antonescu C.R., Riedel E., Brennan M.F. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003 Sep; 238 (3): 358–70. doi: 10.1097/01.sla.0000086542.11899.38.Singer S., Antonescu C.R., Riedel E., Brennan M.F. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003 Sep; 238 (3): 358–70. doi: 10.1097/01.sla.0000086542.11899.38.Coindre J.M., Pedeutour F., Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch. 2010 Feb; 456(2): 167–79. doi: 10.1007/s00428-009-0815-x.Coindre J.M., Pedeutour F., Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch. 2010 Feb; 456(2): 167–79. doi: 10.1007/s00428-009-0815-x.Aurello P., Virgilio E., Sirimarco D., Novi L., D’Angelo F., Ramacciato G. Dedifferentiated liposarcoma of the retroperitoneum with osteosarcomatous component. Int J Surg Pathol. 2013 Jun; 21(3): 314–5. doi: 10.1177/1066896913476749.Aurello P., Virgilio E., Sirimarco D., Novi L., D’Angelo F., Ramacciato G. Dedifferentiated liposarcoma of the retroperitoneum with osteosarcomatous component. Int J Surg Pathol. 2013 Jun; 21(3): 314–5. doi: 10.1177/1066896913476749.Binh M.B., Guillou L., Hostein I., Château M.C., Collin F., Aurias A., Binh B.N., Stoeckle E., Coindre J.M. Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk: a study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas. Am J Surg Pathol. 2007 Oct; 31(10): 1557–66. doi: 10.1097/PAS.0b013e31804b4109.Binh M.B., Guillou L., Hostein I., Château M.C., Collin F., Aurias A., Binh B.N., Stoeckle E., Coindre J.M. Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk: a study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas. Am J Surg Pathol. 2007 Oct; 31(10): 1557–66. doi: 10.1097/PAS.0b013e31804b4109.Evans H.L., Khurana K.K., Kemp B.L., Ayala A.G. Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma. Am J Surg Pathol. 1994 Nov; 18(11): 1150–7. doi:10.1097/00000478199411000-00009.Evans H.L., Khurana K.K., Kemp B.L., Ayala A.G. Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma. Am J Surg Pathol. 1994 Nov; 18(11): 1150–7. doi:10.1097/00000478199411000-00009.Yoshida A., Ushiku T., Motoi T., Shibata T., Fukayama M., Tsuda H. Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant. Am J Surg Pathol. 2010 Sep; 34(9): 1361–6. doi: 10.1097/PAS.0b013e3181ebcc45.Yoshida A., Ushiku T., Motoi T., Shibata T., Fukayama M., Tsuda H. Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant. Am J Surg Pathol. 2010 Sep; 34(9): 1361–6. doi: 10.1097/PAS.0b013e3181ebcc45.Chibon F., Mariani O., Derré J., Malinge S., Coindre J.M., Guillou L., Lagacé R., Aurias A. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet. 2002 Nov; 139(1): 24–9. doi: 10.1016/S0165-4608(02)00614-3.Chibon F., Mariani O., Derré J., Malinge S., Coindre J.M., Guillou L., Lagacé R., Aurias A. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet. 2002 Nov; 139(1): 24–9. doi: 10.1016/S0165-4608(02)00614-3.Coindre J.M., Hostein I., Maire G., Derré J., Guillou L., Leroux A., Ghnassia J.P., Collin F., Pedeutour F., Aurias A. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol. 2004 Jul; 203(3): 822–30. doi: 10.1002/path.1579.Coindre J.M., Hostein I., Maire G., Derré J., Guillou L., Leroux A., Ghnassia J.P., Collin F., Pedeutour F., Aurias A. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol. 2004 Jul; 203(3): 822–30. doi: 10.1002/path.1579.Coindre J.M., Mariani O., Chibon F., Mairal A., De Saint Aubain Somerhausen N., Favre-Guillevin E., Bui N.B., Stoeckle E., Hostein I., Aurias A. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol. 2003 Mar; 16(3): 256–62. doi: 10.1097/01.MP.0000056983.78547.77.Coindre J.M., Mariani O., Chibon F., Mairal A., De Saint Aubain Somerhausen N., Favre-Guillevin E., Bui N.B., Stoeckle E., Hostein I., Aurias A. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol. 2003 Mar; 16(3): 256–62. doi: 10.1097/01.MP.0000056983.78547.77.Antonescu C.R., Tschernyavsky S.J., Decuseara R., Leung D.H., Woodruff J.M., Brennan M.F., Bridge J.A., Neff J.R., Goldblum J.R., Ladanyi M. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001 Dec; 7(12): 3977–87.Antonescu C.R., Tschernyavsky S.J., Decuseara R., Leung D.H., Woodruff J.M., Brennan M.F., Bridge J.A., Neff J.R., Goldblum J.R., Ladanyi M. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001 Dec; 7(12): 3977–87.Schwab J.H., Boland P.J., Antonescu C., Bilsky M.H., Healey J.H. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer 2007 Oct; 110 (8): 1815–22. doi: 10.1002/cncr.22992.Schwab J.H., Boland P.J., Antonescu C., Bilsky M.H., Healey J.H. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer 2007 Oct; 110 (8): 1815–22. doi: 10.1002/cncr.22992.Aman P., Ron D., Mandahl N., Fioretos T., Heim S., Arheden K., Willén H., Rydholm A., Mitelman F. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12; 16)(q 13;p 11). Genes Chromosomes Cancer. 1992; 5 (4): 278–85.Aman P., Ron D., Mandahl N., Fioretos T., Heim S., Arheden K., Willén H., Rydholm A., Mitelman F. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12; 16)(q 13;p 11). Genes Chromosomes Cancer. 1992; 5 (4): 278–85.Knight J.C., Renwick P.J., Cin P.D., Fletcher C.D. Translocation t(12; 16)(q 13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res. 1995 Jun; 55: 24–7.Knight J.C., Renwick P.J., Cin P.D., Fletcher C.D. Translocation t(12; 16)(q 13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res. 1995 Jun; 55: 24–7.Ron D., Habener J.F. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev. 1992 Mar; 6(3): 439–53. doi: 10.1101/gad.6.3.439.Ron D., Habener J.F. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev. 1992 Mar; 6(3): 439–53. doi: 10.1101/gad.6.3.439.Powers C.A., Mathur M., Raaka B.M., Ron D., Samuels H.H. Is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol. 1998 Jun; 12(1): 4–18. doi: 10.1210/mend.12.1.0043.Powers C.A., Mathur M., Raaka B.M., Ron D., Samuels H.H. Is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol. 1998 Jun; 12(1): 4–18. doi: 10.1210/mend.12.1.0043.Kuroda M., Ishida T., Takanashi M., Satoh M., Machinami R., Watanabe T. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol. 1997 Sep; 151(3): 735–44.Kuroda M., Ishida T., Takanashi M., Satoh M., Machinami R., Watanabe T. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol. 1997 Sep; 151(3): 735–44.Gebhard S., Coindre J.M., Michels J.J., Terrier P., Bertrand G., Trassard M., Taylor S., Château M.C., Marquès B., Picot V., Guillou L. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2002 May; 26(5): 601–16. doi: 10.1097/00000478-200205000-00006.Gebhard S., Coindre J.M., Michels J.J., Terrier P., Bertrand G., Trassard M., Taylor S., Château M.C., Marquès B., Picot V., Guillou L. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2002 May; 26(5): 601–16. doi: 10.1097/00000478-200205000-00006.Hornick J.L., Bosenberg M.W., Mentzel T., McMenamin M.E., Oliveira A.M., Fletcher C.D. Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases. Am J Surg Pathol. 2004 Oct; 28(10): 1257–67. doi: 10.1097/01.pas.0000135524.73447.4a.Hornick J.L., Bosenberg M.W., Mentzel T., McMenamin M.E., Oliveira A.M., Fletcher C.D. Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases. Am J Surg Pathol. 2004 Oct; 28(10): 1257–67. doi: 10.1097/01.pas.0000135524.73447.4a.Crago A.M., Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol. 2011 Jul; 23(4): 373–8. doi: 10.1097/CCO.0b013e32834796e6.Crago A.M., Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol. 2011 Jul; 23(4): 373–8. doi: 10.1097/CCO.0b013e32834796e6.McCormick D., Mentzel T., Beham A., Fletcher C.D. Dedifferentiated liposarcoma: clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol. 1994 Dec; 18(12): 1213–23. doi: 10.1097/00000478-199412000-00004.McCormick D., Mentzel T., Beham A., Fletcher C.D. Dedifferentiated liposarcoma: clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol. 1994 Dec; 18(12): 1213–23. doi: 10.1097/00000478-199412000-00004.Mertens F., Fletcher C.D., Dal Cin P., De Wever I., Mandahl N., Mitelman F., Rosai J., Rydholm A., Sciot R., Tallini G., Van den Berghe H., Vanni R., Willén H. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and Morphology. Genes Chromosomes Cancer. 1998 May; 22(1): 16–25.Mertens F., Fletcher C.D., Dal Cin P., De Wever I., Mandahl N., Mitelman F., Rosai J., Rydholm A., Sciot R., Tallini G., Van den Berghe H., Vanni R., Willén H. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and Morphology. Genes Chromosomes Cancer. 1998 May; 22(1): 16–25.Ghadimi M.P., Liu P., Peng T., Bolshakov S., Young E.D., Torres K.E., Colombo C., Hoffman A., Broccoli D., Hornick J.L., Lazar A.J., Pisters P., Pollock R.E., Lev D. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011 Dec; 117(23): 5359–69. doi: 10.1002/cncr.26195.Ghadimi M.P., Liu P., Peng T., Bolshakov S., Young E.D., Torres K.E., Colombo C., Hoffman A., Broccoli D., Hornick J.L., Lazar A.J., Pisters P., Pollock R.E., Lev D. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011 Dec; 117(23): 5359–69. doi: 10.1002/cncr.26195.Li C., Shen Y., Ren Y., Liu W., Li M., Liang W., Liu C., Li F. Oncogene Mutation Profiling Reveals Poor Prognosis Associated with FGFR1/3 Mutation in Liposarcoma. Hum Pathol. 2016 Sep; 55: 143–50. doi: 10.1016/j.humpath.2016.05.006.Li C., Shen Y., Ren Y., Liu W., Li M., Liang W., Liu C., Li F. Oncogene Mutation Profiling Reveals Poor Prognosis Associated with FGFR1/3 Mutation in Liposarcoma. Hum Pathol. 2016 Sep; 55: 143–50. doi: 10.1016/j.humpath.2016.05.006.Somaiah N., Beird H.C., Barbo A., Song J., Mills Shaw K.R., Wang W.L., Eterovic K., Chen K., Lazar A., Conley A.P., Ravi V., Hwu P., Futreal A., Simon G., Meric-Bernstam F., Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr; 9(28): 19891–99. doi: 10.18632/oncotarget.24924.Somaiah N., Beird H.C., Barbo A., Song J., Mills Shaw K.R., Wang W.L., Eterovic K., Chen K., Lazar A., Conley A.P., Ravi V., Hwu P., Futreal A., Simon G., Meric-Bernstam F., Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr; 9(28): 19891–99. doi: 10.18632/oncotarget.24924.Movva S., Wen W., Chen W., Millis S.Z., Gatalica Z., Reddy S., von Mehren M., Van Tine B.A. Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets. Oncotarget. 2015 May 20; 6(14): 12234–47. doi: 10.18632/oncotarget.3498.Movva S., Wen W., Chen W., Millis S.Z., Gatalica Z., Reddy S., von Mehren M., Van Tine B.A. Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets. Oncotarget. 2015 May 20; 6(14): 12234–47. doi: 10.18632/oncotarget.3498.Kim J.R., Moon Y.J., Kwon K.S., Bae J.S., Wagle S., Kim K.M., Park H.S., Lee H., Moon W.S., Chung M.J., Kang M.J., Jang K.Y. Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas. PLoS One. 2013 Dec; 8(12): e82870. doi: 10.1371/journal.pone.0082870.Kim J.R., Moon Y.J., Kwon K.S., Bae J.S., Wagle S., Kim K.M., Park H.S., Lee H., Moon W.S., Chung M.J., Kang M.J., Jang K.Y. Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas. PLoS One. 2013 Dec; 8(12): e82870. doi: 10.1371/journal.pone.0082870.Park H.K., Kim M., Sung M., Lee S.E., Kim Y.J., Choi Y.L. Status of programmed death-ligand 1 expression in sarcomas. J Transl Med. 2018 Nov; 16(1): 303. doi: 10.1186/s12967-018-1658-5.Park H.K., Kim M., Sung M., Lee S.E., Kim Y.J., Choi Y.L. Status of programmed death-ligand 1 expression in sarcomas. J Transl Med. 2018 Nov; 16(1): 303. doi: 10.1186/s12967-018-1658-5.Феденко А.А., Бохян А.Ю., Горбунова В.А., Махсон А.Н., Тепляков В.В. Практические рекомендации по лекарственному лечению сарком мягких тканей. Рекомендации Восточно-европейской группы по изучению сарком. Злокачественные опухоли. 2018; 8(3)s2: 240–49. doi: 10.18027/2224–5057–2018–8–3s2–240–249.Fedenko A.A., Bokhyan A.Yu., Gorbunova V.A., Makhson A.N., Teplyakov V.V. Practical recommendations for the treatment of soft tissue sarcomas. Recommendations of the East European Sarcoma Study Group. Malignant tumors. 2018; 8(3) s2: 240–49. (in Russian). doi: 10.18027/2224–5057–2018–8–3s2–240–249.The ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 23 (Suppl. 7): vii92–99, 2012. doi: 10.1093/annonc/mds253.The ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 23 (Suppl. 7): vii92–99, 2012. doi: 10.1093/annonc/mds253.Thomas J.M. Retroperitoneal sarcoma. Br J Surg. 2007 Sep; 94(9): 1057–8. doi: 10.1002/bjs.5967.Thomas J.M. Retroperitoneal sarcoma. Br J Surg. 2007 Sep; 94(9): 1057–8. doi: 10.1002/bjs.5967.Hughes T.M., Spillane A.J. Imaging of soft tissue tumours. Br J Surg. 2000 Mar; 87(3): 259–60. doi:10.1046/j.1365-2168.2000.01412.x.Hughes T.M., Spillane A.J. Imaging of soft tissue tumours. Br J Surg. 2000 Mar; 87(3): 259–60. doi:10.1046/j.1365-2168.2000.01412.x.Engström K., Bergh P., Gustafson P., Hultborn R., Johansson H., Löfvenberg R., Zaikova O., Trovik C., Wahlström O., Bauer H.C. Liposarcoma: outcome based on the Scandinavian Sarcoma Group register. Cancer. 2008 Oct 1; 113(7): 1649–56. doi: 10.1002/cncr.23784.Engström K., Bergh P., Gustafson P., Hultborn R., Johansson H., Löfvenberg R., Zaikova O., Trovik C., Wahlström O., Bauer H.C. Liposarcoma: outcome based on the Scandinavian Sarcoma Group register. Cancer. 2008 Oct 1; 113(7): 1649–56. doi: 10.1002/cncr.23784.Gronchi A., Pollock R.E. Quality of local treatment or biology of the tumor: which are the trump cards for loco-regional control of retroperitoneal sarcoma? Ann Surg Oncol. 2013 Jul; 20(7): 2111–3. doi: 10.1245/s10434-013-2971-0.Gronchi A., Pollock R.E. Quality of local treatment or biology of the tumor: which are the trump cards for loco-regional control of retroperitoneal sarcoma? Ann Surg Oncol. 2013 Jul; 20(7): 2111–3. doi: 10.1245/s10434-013-2971-0.Bonvalot S., Rivoire M., Castaing M., Stoeckle E., Le Cesne A., Blay J.Y., Laplanche A. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009 Jan 1; 27(1): 31–7. doi: 10.1200/JCO.2008.18.0802.Bonvalot S., Rivoire M., Castaing M., Stoeckle E., Le Cesne A., Blay J.Y., Laplanche A. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009 Jan 1; 27(1): 31–7. doi: 10.1200/JCO.2008.18.0802.Eilber F.C., Eilber F.R., Eckardt J., Rosen G., Riedel E., Maki R.G., Brennan M.F., Singer S. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004 Oct; 240(4): 686–95. doi: 10.1097/01.sla.0000141710.74073.0d.Eilber F.C., Eilber F.R., Eckardt J., Rosen G., Riedel E., Maki R.G., Brennan M.F., Singer S. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004 Oct; 240(4): 686–95. doi: 10.1097/01.sla.0000141710.74073.0d.Gronchi A., Lo Vullo S., Fiore M., Mussi C., Stacchiotti S., Collini P., Lozza L., Pennacchioli E., Mariani L., Casali P.G. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009 Jan; 27(1): 24–30. doi: 10.1200/JCO.2008.17.8871.Gronchi A., Lo Vullo S., Fiore M., Mussi C., Stacchiotti S., Collini P., Lozza L., Pennacchioli E., Mariani L., Casali P.G. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009 Jan; 27(1): 24–30. doi: 10.1200/JCO.2008.17.8871.Pervaiz N., Colterjohn N., Farrokhyar F., Tozer R., Figueredo A., Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008 Aug 1; 113(3): 573–81. doi: 10.1002/cncr.23592.Pervaiz N., Colterjohn N., Farrokhyar F., Tozer R., Figueredo A., Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008 Aug 1; 113(3): 573–81. doi: 10.1002/cncr.23592.Woll P.J., Reichardt P., Le Cesne A., Bonvalot S., Azzarelli A., Hoekstra H.J., Leahy M., Van Coevorden F., Verweij J., Hogendoorn P.C., Ouali M., Marreaud S., Bramwell V.H., Hohenberger P.; EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012 Oct; 13(10): 1045–54. doi: 10.1016/S1470-2045(12)70346-7.Woll P.J., Reichardt P., Le Cesne A., Bonvalot S., Azzarelli A., Hoekstra H.J., Leahy M., Van Coevorden F., Verweij J., Hogendoorn P.C., Ouali M., Marreaud S., Bramwell V.H., Hohenberger P.; EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012 Oct; 13(10): 1045–54. doi: 10.1016/S1470-2045(12)70346-7.Beane J.D., Yang J.C., White D., Steinberg S.M., Rosenberg S.A., Rudloff U. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol. 2014 Aug; 21(8): 2484–9. doi: 10.1245/s10434-014-3732-4.Beane J.D., Yang J.C., White D., Steinberg S.M., Rosenberg S.A., Rudloff U. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol. 2014 Aug; 21(8): 2484–9. doi: 10.1245/s10434-014-3732-4.Harrison L.B., Franzese F., Gaynor J.J., Brennan M.F. Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys. 1993 Sep 30; 27(2): 259–65. doi: 10.1016/0360-3016(93)90236.Harrison L.B., Franzese F., Gaynor J.J., Brennan M.F. Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys. 1993 Sep 30; 27(2): 259–65. doi: 10.1016/0360-3016(93)90236.Yang J.C., Chang A.E., Baker A.R., Sindelar W.F., Danforth D.N., Topalian S.L., DeLaney T., Glatstein E., Steinberg S.M., Merino M.J., Rosenberg S.A. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998 Jan; 16(1): 197–203. doi: 10.1200/JCO.1998.16.1.197.Yang J.C., Chang A.E., Baker A.R., Sindelar W.F., Danforth D.N., Topalian S.L., DeLaney T., Glatstein E., Steinberg S.M., Merino M.J., Rosenberg S.A. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998 Jan; 16(1): 197–203. doi: 10.1200/JCO.1998.16.1.197.Mohindra P., Neuman H.B., Kozak K.R. The role of radiation in retroperitoneal sarcomas. Curr Treat Options Oncol. 2013 Sep; 14(3): 425–41. doi: 10.1007/s11864-013-0236-6.Mohindra P., Neuman H.B., Kozak K.R. The role of radiation in retroperitoneal sarcomas. Curr Treat Options Oncol. 2013 Sep; 14(3): 425–41. doi: 10.1007/s11864-013-0236-6.Krikelis D., Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther. 2010 Feb; 10(2): 249–60. doi: 10.1586/era.09.176.Krikelis D., Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther. 2010 Feb; 10(2): 249–60. doi: 10.1586/era.09.176.Constantinidou A., Pollack S., Loggers E., Rodler E., Jones R.L. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther. 2013 Feb; 13(2): 211–23. doi: 10.1586/era.12.161.Constantinidou A., Pollack S., Loggers E., Rodler E., Jones R.L. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther. 2013 Feb; 13(2): 211–23. doi: 10.1586/era.12.161.Jones R.L., Fisher C., Al-Muderis O., Judson I.R. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005 Dec; 41(18): 2853–60. doi: 10.1016/j.ejca.2005.07.023.Jones R.L., Fisher C., Al-Muderis O., Judson I.R. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005 Dec; 41(18): 2853–60. doi: 10.1016/j.ejca.2005.07.023.Schöffski P., Chawla S., Maki R.G., Italiano A., Gelderblom H., Choy E., Grignani G., Camargo V., Bauer S., Rha S.Y., Blay J.Y., Hohenberger P., D’Adamo D., Guo M., Chmielowski B., Le Cesne A., Demetri G.D., Patel S.R. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16; 387(10028): 1629–37. doi: 10.1016/S0140-6736(15)01283-0.Schöffski P., Chawla S., Maki R.G., Italiano A., Gelderblom H., Choy E., Grignani G., Camargo V., Bauer S., Rha S.Y., Blay J.Y., Hohenberger P., D’Adamo D., Guo M., Chmielowski B., Le Cesne A., Demetri G.D., Patel S.R. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16; 387(10028): 1629–37. doi: 10.1016/S0140-6736(15)01283-0.Hoffman A., Lazar A.J., Pollock R.E., Lev D. New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resist Updat. 2011 Feb; 14(1): 52–66. doi: 10.1016/j.drup.2010.11.001.Hoffman A., Lazar A.J., Pollock R.E., Lev D. New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resist Updat. 2011 Feb; 14(1): 52–66. doi: 10.1016/j.drup.2010.11.001.Constantinidou A., Pollack S.M., Jones R.L. MDM2 inhibition in liposarcoma: a step in the right direction. Lancet Oncol. 2012 Nov; 13(11): 1070–1. doi: 10.1016/S1470-2045(12)70457-6.Constantinidou A., Pollack S.M., Jones R.L. MDM2 inhibition in liposarcoma: a step in the right direction. Lancet Oncol. 2012 Nov; 13(11): 1070–1. doi: 10.1016/S1470-2045(12)70457-6.Dickson M.A., Tap W.D., Keohan M.L., D’Angelo S.P., Gounder M.M., Antonescu C.R., Landa J., Qin L.X., Rathbone D.D., Condy M.M., Ustoyev Y., Crago A.M., Singer S., Schwartz G.K. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified welldifferentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013 Jun 1; 31(16): 2024–8. doi: 10.1200/JCO.2012.46.5476.Dickson M.A., Tap W.D., Keohan M.L., D’Angelo S.P., Gounder M.M., Antonescu C.R., Landa J., Qin L.X., Rathbone D.D., Condy M.M., Ustoyev Y., Crago A.M., Singer S., Schwartz G.K. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified welldifferentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013 Jun 1; 31(16): 2024–8. doi: 10.1200/JCO.2012.46.5476.Ray-Coquard I., Blay J.Y., Italiano A., Le Cesne A., Penel N., Zhi J., Heil F., Rueger R., Graves B., Ding M., Geho D., Middleton S.A., Vassilev L.T., Nichols G.L., Bui B.N. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, welldifferentiated or dedifferentiated liposarcoma: an exploratory proof-ofmechanism study. Lancet Oncol (2012) 13(11): 1133–40. doi: 10.1016/S1470-2045(12)70474-6.Ray-Coquard I., Blay J.Y., Italiano A., Le Cesne A., Penel N., Zhi J., Heil F., Rueger R., Graves B., Ding M., Geho D., Middleton S.A., Vassilev L.T., Nichols G.L., Bui B.N. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, welldifferentiated or dedifferentiated liposarcoma: an exploratory proof-ofmechanism study. Lancet Oncol (2012) 13(11): 1133–40. doi: 10.1016/S1470-2045(12)70474-6.Conyers R., Young S., Thomas D.M. Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011; 2011: 483154. doi: 10.1155/2011/483154.Conyers R., Young S., Thomas D.M. Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011; 2011: 483154. doi: 10.1155/2011/483154.Park K.W., Halperin D.S., Tontonoz P. Before they were fat: adipocyte progenitors. Cell Metab. 2008 Dec; 8(6): 454–7. doi: 10.1016/j.cmet.2008.11.001.Park K.W., Halperin D.S., Tontonoz P. Before they were fat: adipocyte progenitors. Cell Metab. 2008 Dec; 8(6): 454–7. doi: 10.1016/j.cmet.2008.11.001.

The authors declare that there are no conflicts of interest present.